| Objective: Recombinant Human Adenovirus Type 5 is mainly used in the treatment of advanced nasopharyngeal carcinoma patients.These patients either have recurrent situation,or difficulty in operation,or are inappropriate to accept radiation or chemotherapy.The treatment of primary liver cancer is not included.Now,the literatures or the domestic academic conferences which are associated with Recombinant Human Adenovirus Type 5 only have a few clinical research objects.This study is a kind of systemic clinical research about our hospital.We have the most clinical patients,and would provide reliable basis for the clinical practice.To assess the application value of Recombinant Human Adenovirus Type 5 together with hepatic arterial chemoembolization for the treatment of primary liver cancer,and provide useful evidence for recombinant human adenovirus Type 5.Method: We choose 1080 patients with primary liver cancer in our department from January 2008 to December 2015,in this research,including 704 males and 376 females.The average age was 61 years old(25-79 years old).Besides,Child-Pugh grade for liver function included 494 cases of level A and 586 cases of level B;612 cases have more than 400?g/L of AFP,202 patients have less than 20?g/L,and 266 cases between these two levels.We divided all these patients into two groups: experimental group and control group,each group has 540 patients.Based on RECIST criteria,we judge whether there are changes of the tumor bodies.The level of AFP?coagulation function before and after the different treatment and Karnofsky?adverse effects after the treatment should be analysized.3 months?6 months and 12 months after different treatments,the tumor body would be measured to see if they had any changes of size or distant metastasis had happened.Follow-up survival rate also would be statistically analysised.All the experimental data would be analysised using SPSS 15.0 statistical software,for statistical processing,comparison between measurement data using t test,counting data by chi-square test,P < 0.05 was statistically significant.Result: In this experiment,1080 cases of primary liver cancer patients would accept the curative effect evaluation after the treatment of TACE.After the comparison,patients of the experimental group had smaller tumor,there had statistically significant difference between the two groups.After the treatment,AFP of the peripheral blood had a statistically significant difference between the two groups(X~2 = 3.061,P = 3.061 < 0.05),the experimental group had better curative effect.There was no significant difference of blood coagulation function between these two groups(X~2 = 0.289,P = 0.773 > 0.05).There was no statistically significant differences between the two groups in the adverse reactions within 1 weeks after the different treatments.Between these two groups,the survival rate had no statistically significant within 6 months after the different treatment,however,the survival rate within 12 months had statistically significant differences,show that human recombinant adenovirus type 5 together with hepatic arterial chemoembolization of got better achievement than the control group.Two groups had no statistically significant difference after the first six months in cumulative recurrence and distant metastasis,but after 12 months,it showed statistically significant differences between these two groups.The experiment group achieved better curative effects.Conclusion: Human recombinant adenovirus type 5 together with transcatheter hepatic arterial chemoembolization has achieved better clinical results in the treatment of primary liver cancer,what's more,there has synergy effects between them.They can promote each other.Recombinant human adenovirus type 5 has slight adverse effects in patients and is regarded as a kind of effective clinical drug treatment for primary liver cancer. |
PDF Full Text Request